Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Osteoporosis
Published in: Archives of Osteoporosis 1/2020

01-12-2020 | Splenectomy | Original Article

Bone mineral density in transfusion-dependent thalassemia patients and its associated factors in Southern Iran

Authors: Mohammadreza Bordbar, Gholamhossein Ranjbar Omrani, Sezaneh Haghpanah, Forough Saki, Mehran Karimi, Omidreza Zekavat

Published in: Archives of Osteoporosis | Issue 1/2020

Login to get access

Abstract

Summary

Despite the significant improvements in the management of thalassemia, there are growing concerns regarding their long-term complications. We showed that low bone mass is one of the most prevalent complications among these patients. Insufficient physical activity and hypogonadism are the main possible associated factors followed by DM and insufficient sun exposure.

Purpose

Despite the significant improvements in the management of transfusion-dependent thalassemia (TDT), there are growing concerns regarding their long-term complications.

Methods

This cross-sectional study included 615 TDT patients who were registered and followed in a comprehensive thalassemia clinic in Southern Iran. We measured serum biochemical tests and bone mineral density in all patients. We recorded physical activity and sun exposure subjectively, and an endocrinologist visited and examined all the patients. A group of age- and gender-matched healthy volunteers participated in the study as the control group.

Results

The mean age of the studied population was 28.4 ± 7.7 years, and 55.8% were female. The prevalence of vitamin D deficiency was 45.6% and 54.4% in TDT patients and the control group. A portion of TDT patients suffered from different endocrinopathies, which included hypogonadism (49.8%), diabetes mellitus (17.2%), hypoparathyroidism (14.6%), and hypothyroidism (6.3%). The prevalence of low bone mass in patients with TDT was 48.3 and 74.6% in the femoral and lumbar bones, respectively. Low physical activity, insufficient sun exposure, diabetes mellitus, and hypogonadism were associated with low bone mass.

Conclusion

Low bone mass is highly prevalent among TDT patients in Southern Iran. Insufficient physical activity and hypogonadism are the main possible associated factors, followed by DM and insufficient sun exposure.
Literature
1.
Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H (2019) Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients. Expert Rev Hematol 12(11):997–1003PubMed
2.
Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A (2019) Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience. J Clin Res Pediatr Endocrinol 11(2):110–117PubMedPubMedCentral
3.
Bordbar M, Bozorgi H, Saki F, Haghpanah S, Karimi M, Bazrafshan A, Zekavat OR (2019) Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran. J Endocrinol Investig 42(12):1467–1476
4.
De Sanctis V, Soliman AT, El-Hakim I, Christou S, Mariannis D, Karimi M et al (2019) Marital status and paternity in patients with transfusion-dependent thalassemia (TDT) and non transfusion-dependent thalassemia (NTDT): an ICET - a survey in different countries. Acta Biomed 90(3):225–237PubMedPubMedCentral
5.
Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N, Tournis S (2016) Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporos Int 27(12):3409–3425PubMed
6.
Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127(2):127–139PubMed
7.
De Sanctis V, Soliman AT, Canatan D, Tzoulis P, Daar S, Di Maio S et al (2019) An ICET-a survey on occult and emerging endocrine complications in patients with beta-thalassemia major: conclusions and recommendations. Acta Biomed 89(4):481–489PubMed
8.
Tzoulis P, Ang AL, Shah FT, Berovic M, Prescott E, Jones R, Barnard M (2014) Prevalence of low bone mass and vitamin D deficiency in beta-thalassemia major. Hemoglobin. 38(3):173–178PubMed
9.
Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P (1995) The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 42(3):279–287
10.
Chatterjee R, Katz M (2000) Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol 53(1):33–42
11.
Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C et al (2008) Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol 69(2):202–207
12.
Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N (2002) Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Investig 25(4):338–344
13.
De Sanctis V, Soliman AT, Canatan D, Elsedfy H, Karimi M, Daar S et al (2018) An ICET- a survey on hypoparathyroidism in patients with thalassaemia major and intermedia: a preliminary report. Acta Biomed 88(4):435–444PubMed
14.
Voskaridou E, Terpos E (2008) Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev 6(Suppl 1):86–93PubMed
15.
Skordis N, Efstathiou E, Kyriakou A, Toumba M (2008) Hormonal dysregulation and bones in thalassaemia--an overview. Pediatr Endocrinol Rev 6(Suppl 1):107–115PubMed
16.
De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR et al (1996) Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 155(5):368–372PubMed
17.
Terpos E, Voskaridou E (2010) Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 1202:237–243PubMed
18.
Johanson NA (1990) Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am 21(1):191–198PubMed
19.
Origa R, Fiumana E, Gamberini MR, Armari S, Mottes M, Sangalli A et al (2005) Osteoporosis in beta-thalassemia: clinical and genetic aspects. Ann N Y Acad Sci 1054:451–456PubMed
20.
Al-Agha AE, Bawahab NS, Nagadi SA, Alghamdi SA, Felemban DA, Milyani AA (2020) Endocrinopathies complicating transfusion-dependent hemoglobinopathy. Saudi Med J 41(2):138–143PubMed
21.
Abbasi S, Asl JF, Zadeh LM, Mirdoraghi M (2018) Measurement bone mineral density (BMD) of patients with beta thalassemia. Data Brief 19:1021–1024PubMedPubMedCentral
22.
Larijani B, Moayyeri A, Keshtkar AA, Hossein-Nezhad A, Soltani A, Bahrami A, Omrani GH, Rajabian R, Nabipour I (2006) Peak bone mass of Iranian population: the Iranian Multicenter Osteoporosis Study. J Clin Densitom 9(3):367–374PubMed
23.
Pellegrino F, Zatelli MC, Bondanelli M, Carnevale A, Cittanti C, Fortini M, Gamberini MR, Giganti M, Ambrosio MR (2019) Dual-energy X-ray absorptiometry pitfalls in thalassemia major. Endocrine. 12:1–4
24.
Bozzola M, Bozzola E, Montalbano C, Stamati FA, Ferrara P, Villani A (2018) Delayed puberty versus hypogonadism: a challenge for the pediatrician. Ann Pediatr Endocrinol Metab 23(2):57–61PubMedPubMedCentral
25.
Kennel KA, Drake MT, Hurley DL (2010) Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 85(8):752–757 quiz 7-8PubMedPubMedCentral
26.
Baldini M, Forti S, Orsatti A, Ulivieri FM, Airaghi L, Zanaboni L, Cappellini MD (2014) Bone disease in adult patients with beta-thalassaemia major: a case-control study. Intern Emerg Med 9(1):59–63PubMed
27.
Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S (2007) Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr 44(1):29–32PubMed
28.
Valizadeh N, Farrokhi F, Alinejad V, Said Mardani S, Valizadeh N, Hejazi S et al (2014) Bone density in transfusion dependent thalassemia patients in Urmia, Iran. Iran J Ped Hematol Oncol 4(2):68–71PubMedPubMedCentral
29.
Meena MC, Hemal A, Satija M, Arora SK, Bano S (2015) Comparison of bone mineral density in thalassemia major patients with healthy controls. Adv Hematol 2015:648349PubMedPubMedCentral
30.
Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R, Choudhry VP (2018) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus 34(1):163–165PubMed
31.
Aslan I, Canatan D, Balta N, Kacar G, Dorak C, Ozsancak A et al (2012) Bone mineral density in thalassemia major patients from Antalya, Turkey. Int J Endocrinol 2012:573298PubMedPubMedCentral
32.
Benigno V, Bertelloni S, Baroncelli GI, Bertacca L, Di Peri S, Cuccia L et al (2003) Effects of thalassemia major on bone mineral density in late adolescence. J Pediatr Endocrinol Metab 16(Suppl 2):337–342PubMed
33.
Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ, for the Thalassemia Clinical Research Network (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543–557PubMed
34.
Mohkam M, Shamsian BS, Gharib A, Nariman S, Arzanian MT (2008) Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol 23(6):971–976PubMed
35.
Chan YL, Pang LM, Chik KW, Cheng JC, Li CK (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32(7):492–497PubMed
36.
Fung EB, Xu Y, Kwiatkowski JL, Vogiatzi MG, Neufeld E, Olivieri N et al (2010) Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr 157(4):641–647 7 e1-2PubMedPubMedCentral
37.
Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B, Airaghi L, Zanaboni L, Cappellini MD (2010) Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 89(12):1207–1213PubMed
38.
Trachtenberg F, Foote D, Martin M, Carson S, Coates T, Beams O et al (2010) Pain as an emergent issue in thalassemia. Am J Hematol 85(5):367–370PubMedPubMedCentral
39.
Dede AD, Tournis S, Dontas I, Trovas G (2014) Type 2 diabetes mellitus and fracture risk. Metabolism. 63(12):1480–1490PubMed
40.
Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ (2006) prevalence of fractures among the thalassemia syndromes in North America. Bone. 38(4):571–575PubMed
41.
Hamann C, Kirschner S, Gunther KP, Hofbauer LC (2012) Bone, sweet bone--osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol 8(5):297–305PubMed
42.
Leidig-Bruckner G, Ziegler R (2001) Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 109(Suppl 2):S493–S514PubMed
43.
Hofbauer LC, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22(9):1317–1328PubMed
44.
Polat HB, Beyazal MS (2018) The effect of cholecystectomy on 25-hydroxyvitamin D levels and bone mineral density in postmenopausal women. Arch Osteoporos 13(1):61PubMed
45.
Baschant U, Rauner M, Balaian E, Weidner H, Roetto A, Platzbecker U, Hofbauer LC (2016) Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. Haematologica. 101(12):1499–1507PubMedPubMedCentral
46.
Momeni A, Rapp S, Donneys A, Buchman SR, Wan DC (2016) Clinical use of deferoxamine in distraction osteogenesis of irradiated bone. J Craniofac Surg 27(4):880–882PubMedPubMedCentral
47.
Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC et al (2014) Thalassemia bone disease: a 19-year longitudinal analysis. J Bone Miner Res 29(11):2468–2473PubMed
48.
Fung EB, Harmatz PR, Milet M, Coates TD, Thompson AA, Ranalli M, Mignaca R, Scher C, Giardina P, Robertson S, Neumayr L, Vichinsky EP, Multi-Center Iron Overload Study Group (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone. 43(1):162–168PubMedPubMedCentral
Metadata
Title
Bone mineral density in transfusion-dependent thalassemia patients and its associated factors in Southern Iran
Authors
Mohammadreza Bordbar
Gholamhossein Ranjbar Omrani
Sezaneh Haghpanah
Forough Saki
Mehran Karimi
Omidreza Zekavat
Publication date
01-12-2020
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2020
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-020-00811-7

Other articles of this Issue 1/2020

Archives of Osteoporosis 1/2020 Go to the issue

Review

Association between diabetic neuropathy and osteoporosis in patients: a systematic review and meta-analysis

Original Article

Targeted vertebral fracture assessment for optimizing fracture prevention in Canada

Original Article

The relationship between platelet count and bone mineral density: results from two independent population-based studies

Original Article

The use of pulse-echo ultrasound in women with a recent non-vertebral fracture to identify those without osteoporosis and/or a subclinical vertebral fracture: a pilot study

Original Article

Development of a model for identification of individuals with high risk of osteoporosis

Original Article

Estimated epidemiology of osteoporosis diagnoses and osteoporosis-related high fracture risk in Germany: a German claims data analysis